Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short term Debt (2016 - 2023)

Amicus Therapeutics (FOLD) has disclosed Short term Debt for 13 consecutive years, with $13.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Short term Debt fell 32.5% year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Jun 2023, down 32.5%, and an annual FY2022 reading of $21.4 million, up 13.32% over the prior year.
  • Short term Debt was $13.0 million for Q2 2023 at Amicus Therapeutics, up from $12.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $21.4 million in Q4 2022 and bottomed at $8.9 million in Q4 2020.
  • Average Short term Debt over 4 years is $17.0 million, with a median of $19.2 million recorded in 2022.
  • The sharpest move saw Short term Debt soared 112.36% in 2021, then tumbled 33.85% in 2023.
  • Year by year, Short term Debt stood at $8.9 million in 2020, then skyrocketed by 112.36% to $18.9 million in 2021, then rose by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • Business Quant data shows Short term Debt for FOLD at $13.0 million in Q2 2023, $12.7 million in Q1 2023, and $21.4 million in Q4 2022.